EPOGEN/PROCRIT Drug Profile

✉ Email this page to a colleague

Summary for Tradename: EPOGEN/PROCRIT

Patents:	5
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for EPOGEN/PROCRIT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPOGEN/PROCRIT

Recent Clinical Trials for EPOGEN/PROCRIT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sandoz	Phase 3

See all EPOGEN/PROCRIT clinical trials

Recent Litigation for EPOGEN/PROCRIT

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Ameranth, Inc. v. Starbucks Corporation	2013-05-06

See all EPOGEN/PROCRIT litigation

Pharmacology for EPOGEN/PROCRIT

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EPOGEN/PROCRIT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EPOGEN/PROCRIT Derived from Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	See Plans and Pricing	2012-08-15	Company disclosures
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	See Plans and Pricing	2013-08-20	Company disclosures
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	See Plans and Pricing	2003-12-13	Company disclosures
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	See Plans and Pricing	2015-05-26	Company disclosures
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	See Plans and Pricing	2016-09-21	Company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for EPOGEN/PROCRIT Derived from Patent Text Search

These patents were obtained by searching patent claims